The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naïve predominantly black African HIV patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naïve predominantly black African HIV patients ; volume:11 ; number:1 ; day:10 ; month:11 ; year:2008 ; pages:1-2 ; date:12.2008
Journal of the International AIDS Society / International AIDS Society ; 11, Heft 1 (10.11.2008), 1-2, 12.2008
- Urheber
-
Das, S.
- Beteiligte Personen und Organisationen
-
Arumainayagam, J.
Kumari, B.
Chandramani, S.
Riddell, L.
Ghanem, M.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-11-S1-P15
- URN
-
urn:nbn:de:1111-2016052054030
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Das, S.
- Arumainayagam, J.
- Kumari, B.
- Chandramani, S.
- Riddell, L.
- Ghanem, M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal
Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
Response of treatment-naive brain metastases to stereotactic radiosurgery
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate
Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal
Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
Response of treatment-naive brain metastases to stereotactic radiosurgery
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate
Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal
Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
Response of treatment-naive brain metastases to stereotactic radiosurgery
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate
Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma